Gebert et al. identified four shared FSP neoantigens (Nacad [FSP-1], Maz [FSP-1], Senp6 [FSP-1], and Xirp1 [FSP-1]) capable of inducing CD4/CD8 T cell responses in mouse models, and demonstrated that combination of only four FSPs significantly increased FSP-specific adaptive immunity, reduced tumor burden, and improved survival in LS mice with CRC [69]. Here, CD8A is linked to neoplasm.